King Pharmaceuticals KG Increase (Decrease) in Accrued Investment Income Receivable

Increase (Decrease) in Accrued Investment Income Receivable at other companies

Universal Insurance HoldingsUVE

$505.75K+27.7%

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's increase (decrease) in accrued investment income receivable?: King Pharmaceuticals (KG) reported increase (decrease) in accrued investment income receivable of -$123K in Q1 2026.
What does increase (decrease) in accrued investment income receivable mean?: The net change in interest and dividend income earned on investment assets but not yet received in cash. This metric tracks the accrual of investment returns and the timing of cash inflows from the company's investment portfolio. It provides insight into the yield performance and cash conversion cycle of the company's assets.